Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
"...related kits and support services with a MINIMUM VALUE* of £150 million for the first 14 weeks. Based on this initial period, a further £100 million of revenue could be expected for the subsequent 10 weeks, however volumes can be varied up or down subject to certain notice criteria given by the DHSC."
*Capitals are mine for emphasis.
Taylor Quant on Twitter last night mooted that the Q16 and Q32 instruments were to be used in hospitals to triage which wards those with and without Flu and or Covid were to be admitted.
Q32 for Winterplex use.
We won't know the order value until we see how much Winterplex is being ordered, rather that RT qPCR Assay.
Unfortunately it looks like PHE expect very large hospital admissions in the next 6 months.
In addition to the provision of products, the Company will also provide training and maintenance services for the q16 and q32 instrument platformL
And don’t forgot this nice little add on, we’ll be setting up a training centre next, not cheap them 1/2 days courses and maintenance call outs, lol.
https://www.youtube.com/watch?v=cnfs8wvXgpA&ab_channel=TheCartoonManist
Boom Boom !!!!!
Double BOOM!!!
The DHSC contract is simply the best RNS I’ve ever read! 99% chance they’ll take the extra 700 machines too, which presumably would take the total contract value up to £750m... wow.
OMG it's better than I thought.
Ooooo la la. Nothing else to say literally amazing. Finally released. Well done usual bunch. Gstg
This first phase of the contract will involve the immediate deployment of 300 PCR instruments, related kits and support services with a minimum value of £150 million for the first 14 weeks. Based on this initial period, a further £100 million of revenue could be expected for the subsequent 10 weeks, however volumes can be varied up or down subject to certain notice criteria given by the DHSC.
Elisa Doesalot !!
Novacyt does it all.
Paris, France and Camberley, UK - 29 September 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces it has signed a new supply contract with the UK Department of Health and Social Care (DHSC) for its q16 and q32 Rapid-PCR instrument platforms, exsig® COVID-19 Direct kits and genesig® SARS-CoV-2 Winterplex kits.
This is the second major contract awarded by the DHSC to Primerdesign, the Company's wholly owned molecular diagnostics division, during the COVID-19 pandemic and follows the ongoing contract announced on 27 April 2020 for the supply of its PCR COVID-19 test.
Under the terms of the contract, which is in two phases, Primerdesign will supply its products to the DHSC for up to six months. Phase one has an initial fixed term of 14 weeks with the potential to extend supply by a further 10 weeks. This first phase of the contract will involve the immediate deployment of 300 PCR instruments, related kits and support services with a minimum value of £150 million for the first 14 weeks. Based on this initial period, a further £100 million of revenue could be expected for the subsequent 10 weeks, however volumes can be varied up or down subject to certain notice criteria given by the DHSC.
The second phase of the contract, which is optional by the DHSC, allows for the provision of up to 700 additional PCR instruments, related kits and support services, as well as additional COVID-19 products from the Company's portfolio where required. Depending upon the uptake, phase two of the contract could generate considerably more sales than the first phase.
The intended use of the contract is for Novacyt to support the urgent requirement for COVID-19 testing of patients in the NHS. In addition to the provision of products, the Company will also provide training and maintenance services for the q16 and q32 instrument platforms.
Novacyt has the capacity to meet the demand of both phases of this new contract, as well as to continue to build its sales across international markets.
Graham Mullis, Chief Executive Officer of Novacyt, added:
"I am delighted that Novacyt continues to play a key role in helping the UK fight the COVID-19 pandemic and this second DHSC contract reinforces the Company's important position within UK diagnostics today. Through this contract, we will be working to support the NHS as we approach an expected challenging winter period. The ability to test multiple patients with our market leading COVID-19 kits and instruments designed to provide results in under 60 minutes will help to ensure vital NHS services can continue to function during these difficult times. I am immensely proud of what the Novacyt team continues to deliver and remain confident in the prospects of the business, not only for the short-term, but also for the longer-term."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
Paris, France and Camberley, UK - 29 September 2020 - Novacyt, an international specialist in clinical diagnostics, announces that, further to the announcement on 27 July 2020, the Company has launched a CE-Mark approved serology (antibody) 96-well plate ELISA (enzyme-linked immunosorbent assay) test for the detection of IgG antibodies to SARS-CoV-2 derived from plasma and serum samples.
The test has been launched by Microgen Bioproducts Limited (Microgen), which is part of Novacyt's protein diagnostics division Lab21. The new antibody test complements Novacyt's existing COVID-19 product portfolio, in particular the Company's polymerase chain reaction (PCR) test for COVID-19, to provide clinicians with the diagnostic tools to detect and differentiate between active and prior SARS-CoV-2 infections in patients.
The new antibody test has been validated in a study where 1,673 patient samples (112 positive samples and 1,561 negative samples) were evaluated. The test demonstrated 100% sensitivity in patients that were tested at 14 days after testing positive for COVID-19 by a PCR test. The antibody test also demonstrated 99.4% specificity.
The ELISA test has been designed for use in all established central laboratories and follows a standard ELISA protocol that makes it compatible with most 96-well plate automation systems. Novacyt has sufficient manufacturing capacity to deliver more than three million antibody tests per month initially and the Company is working with its manufacturing partner to ensure this can be increased depending on demand.
Graham Mullis, Chief Executive Officer of Novacyt, commented:
"Novacyt remains committed to supporting the global response to COVID-19 through the delivery of high performance diagnostics. We continue to strengthen our product offering in COVID-19 testing as demand continues and we are delighted to launch an antibody test. We believe an antibody test plays an important role in aiding the diagnosis of COVID-19, as well as increasing our understanding of the disease through screening of populations for infection rates and immunity."
BOOM. 2 of them. Happy days!!!!!